Radar therapeutics emerges with $13.4M to develop smart anti-ageing medicines
Longevity Technology - 24-May-2024Programmable mRNA tech promise precise & safe treatment for disease and age-related conditions
Join the club for FREE to access the whole archive and other member benefits.
Professor at MIT and Co-founder of Radar Therapeutics
Jim Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also the Co-founder of Radar therapeutics, along with Synlogic, Senti Biosciences, Sherlock Biosciences, Cellarity, and Phare Bio
The Collins research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance. He has received numerous awards and honors, including a MacArthur "Genius" Award and the Dickson Prize in Medicine, and he is an elected member of all three national academies - the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine.
Visit website: https://be.mit.edu/directory/james-j-collins
See also: Massachusetts Institute of Technology (MIT) - Private land-grant research university
Details last updated 03-Jun-2024
Programmable mRNA tech promise precise & safe treatment for disease and age-related conditions